Idenix Pharmaceuticals, Inc. To Participate In HCV Panel At Deutsche Bank 31st Annual Health Care Conference And Present At Morgan Stanley Global Healthcare Unplugged Conference

CAMBRIDGE, Mass., April 26 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that Jean-Pierre Sommadossi, Ph.D., Idenix’s chairman and chief executive officer, will participate in the HCV Panel at the Deutsche Bank 31st Annual Health Care Conference on Tuesday, May 2, 2006 at 4:45 p.m. ET at the Sheraton Boston Hotel, Boston, Massachusetts. Additionally, Dr. Sommadossi will present a corporate overview at the upcoming Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 4, 2006 at 2:15 p.m. ET at the Mandarin Oriental Hotel in Miami, Florida.

The live and archived webcast of the Deutsche Bank panel discussion can be accessed at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=27277&item_id=1300189 or under “Calendar of Events” in the Idenix Investor Center at http://www.idenix.com.

The live and archived webcast of the Morgan Stanley Conference presentation can be accessed at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=IDIX&item_id=1298047 or under “Calendar of Events” in the Idenix Investor Center at http://www.idenix.com.

The archived replays will be available on the Idenix website for two weeks following the presentations.

About Idenix

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix’s current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). Idenix’s headquarters are located in Cambridge, Massachusetts and it has drug discovery operations in Montpellier, France and Cagliari, Italy.

Contacts: Idenix Pharmaceuticals, Inc. Amy Sullivan (617) 995-9838 Teri Dahlman (617) 995-9905

Idenix Pharmaceuticals, Inc.

CONTACT: Amy Sullivan, +1-617-995-9838, or Teri Dahlman, +1-617-995-9905,both of Idenix Pharmaceuticals, Inc.

MORE ON THIS TOPIC